Helium plasma dermal resurfacing: Consensus guidelines


Journal Article


John David Holcomb MD, Diane Duncan MD, Michael Lin MD, J. D. McCoy NMD, Richard Gentile MD, Edward Zimmerman MD, Melinda Lacerna MD, Paul G. Ruff MD, and Joseph B. DeLozier MD


Introduction: Nine experienced physician users of a novel helium plasma dermal resurfacing device for heating the skin at a controlled depth to achieve collagen coagulation, tissue contraction, and neocollagenesis convened to discuss their experiences and keys to success with their off‐label use of this device with collectively more than 800 cases performed for facial skin renewal procedures.

Methods: A round table discussion format was used to address a variety of topics including pretreatment considerations, optimum treatment parameters, posttreatment healing regimen, and avoidance and management of side effects and complications. All panelists consented to data collection, analysis, compilation, and publication.

Results: Ideal candidates for the procedure were identified along with optimum treatment parameters and posttreatment care. Strategies for avoidance and management of complications and side effects were discussed.

Conclusions: Consensus guidelines were developed for patient selection, pretreatment considerations, treatment parameters, posttreatment healing regimen, and avoidance and management of complications and side effects.


The authors declared no potential conflicts of interest with respect to the research, authorship, and publication of this article. No funding was received for this article. Drs DiBernardo, Bharti, and Kortesis are paid consultants for Apyx Medical, and Dr Duncan is a member of Apyx Medical’s Medical Advisory Board. The opinions contained herein are those of the authors and do not necessarily represent the official position or policies of Apyx Medical, Inc.

Apyx Medical manufactures and owns the Renuvion®/J-Plasma® technology discussed in this article.


    • Renuvion Dermal Handpiece is indicated for dermatological procedures for the treatment of moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick skin types I, II, or III.
    • Apyx Medical wants to present to you with current scientific discourse. Specific usage outside of the cleared indications may not be safe or effective.


    • Risks associated with the use of the Renuvion Dermal System include but are not limited to hypertrophic scarring, milia/acne, telangiectasia (spider veins), skin discoloration/ hypopigmentation, dormant infection reactivation, infection, bruising or bleeding. Warning: Application of more than one treatment pass in the perioral area, on the forehead, and along the jawline has been associated with hypertrophic scarring.

As with any procedure, individual results may vary. As with all energy devices there are inherent risks associated with its use, refer to the IFU for further information.

back to top